None listed
Conditions
Brief summary
Obstructive sleep apnoea (OSA) affects more than 50% of people with interstitial lung disease (ILD), with inadequate treatment due to poor compliance with current treatments such as CPAP and mouth splints. Supplemental oxygen is a potential treatment for OSA in people with ILD, which is readily available and easy to use, and ovenight oximetry may be helpful for establishing the diagnosis of OSA in people with ILD.
Interventions
Supplemental 100% oxygen at 5 litres/min via nasal cannulae during a single night of overnight polysomnography performed by a sleep scientist at a sleep laboratory. Participants who are using CPAP for the management of obstructive sleep apnoea will be temporarily ceasing CPAP for up to 14 days prior to the first night of overnight polysomnography. The two nights of overnight polysomnography will be performed within 4 weeks with at least 1 night in between each study, and a washout period is not
Supplemental 100% oxygen at 5 litres/min via nasal cannulae during a single night of overnight polysomnography performed by a sleep scientist at a sleep laboratory. Participants who are using CPAP for the management of obstructive sleep apnoea will be temporarily ceasing CPAP for up to 14 days prior to the first night of overnight polysomnography. The two nights of overnight polysomnography will be performed within 4 weeks with at least 1 night in between each study, and a washout period is not required. Participants will be given a pulse oximeter to wear over the fingertip for measurement of overnight oximetry at home over three individual nights without treatment.
Sponsors
Dr Yet Hong Khor
Study design
Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age greater than or equal to 18 years 2. Able to give written informed consent 3. A multidisciplinary diagnosis of fibrotic interstitial lung disease of any aetiology 4. Suspected obstructive sleep apnoea or confirmed diagnosis of obstructive sleep apnoea using overnight polysomnography
Exclusion criteria
1. Use of or eligible for long-term oxygen therapy 2. Use of respiratory stimulants or depressants 3. Stable health condition (defined as hospitalisation for acute medical conditions) in the last 4 weeks before screening 4. Significant co-existing chronic obstructive pulmonary disease (defined as FEV1/FVC <60% on the most recent lung spirometry or extent of emphysema greater than extent of fibrosis on the most recent CT chest)
Outcome results
None listed